ImageneBio, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
ImageneBio, Inc. (IMA) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum of 3.59% for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-14.
Discontinued › Notes › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum · last filed 2023-03-14
- ImageneBio, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2022-06-30 was 3.03%, a 183.18% increase year-over-year.
- ImageneBio, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2021-09-30 was 1.07%, a 127.66% increase year-over-year.
- ImageneBio, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2021-06-30 was 1.07%.
- ImageneBio, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2020-09-30 was 0.47%.
- ImageneBio, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2022 was 3.59%, a 169.92% increase from fiscal 2021.
- ImageneBio, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2021 was 1.33%, a 182.98% increase from fiscal 2020.
- ImageneBio, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2020 was 0.47%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month |
|---|---|---|---|---|
| 2022-12-31 | 3.59% 10-K · filed 2023-03-14 | |||
| 2022-09-30 | 3.03% 10-Q · filed 2022-11-07 | |||
| 2022-06-30 | 3.03% 10-Q · filed 2022-08-11 | 3.03% 10-Q · filed 2022-08-11 | ||
| 2021-12-31 | 1.33% 10-K · filed 2023-03-14 | |||
| 2021-09-30 | 1.07% 10-Q · filed 2022-11-07 | 1.07% 10-Q · filed 2022-11-07 | ||
| 2021-06-30 | 1.07% 10-Q · filed 2022-08-11 | 1.07% 10-Q · filed 2022-08-11 | ||
| 2020-12-31 | 0.47% 10-K · filed 2022-03-17 | |||
| 2020-09-30 | 0.47% 10-Q · filed 2021-11-10 | 0.47% 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B |